Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Roche Holding AG

Market Cap 254B 317B 276B 239B 448B 29,846B 451B 3,026B 1,175B 14,708B 1,189B 1,163B 50,980B P/E 2026 *
17x
P/E 2027 * 15.9x
Enterprise Value 265B 330B 287B 249B 466B 31,070B 469B 3,150B 1,223B 15,312B 1,237B 1,211B 53,071B EV / Sales 2026 *
4.23x
EV / Sales 2027 * 3.97x
Free-Float
88.78%
Yield 2026 *
3.14%
Yield 2027 * 3.21%
Current month+0.48%
6 months+1.40%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 330B
-1.21%-5.37%+39.94%+145.38% 992B
-2.48%-4.17%+51.52%+39.07% 564B
-2.14%-3.68%+16.71%+56.15% 391B
-2.36%-2.30%+23.37%+11.59% 280B
-2.45%-0.84%+23.51%+30.06% 279B
-1.91%-1.06%-42.60%-49.25% 196B
-1.19%-4.65%+16.56%+47.00% 184B
-1.35%-1.68%+14.59%+56.94% 156B
-2.74%-3.67%+5.57%-37.07% 148B
Average -1.51%-2.65%+16.58%+33.32% 354.38B
Weighted average by Cap. -1.59%-3.45%+26.99%+63.39%

Financials

2026 *2027 *
Net sales 62.56B 77.89B 67.86B 58.84B 110B 7,340B 111B 744B 289B 3,617B 292B 286B 12,538B 65.06B 81B 70.57B 61.19B 114B 7,634B 115B 774B 301B 3,762B 304B 298B 13,039B
Net income 15.23B 18.96B 16.52B 14.32B 26.79B 1,786B 26.98B 181B 70.35B 880B 71.15B 69.63B 3,052B 16.24B 20.23B 17.62B 15.28B 28.59B 1,906B 28.79B 193B 75.06B 939B 75.92B 74.29B 3,256B
Net Debt 10.43B 12.99B 11.32B 9.81B 18.36B 1,224B 18.49B 124B 48.21B 603B 48.76B 47.71B 2,091B 3.76B 4.68B 4.07B 3.53B 6.61B 441B 6.66B 44.69B 17.36B 217B 17.55B 17.18B 753B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
18/06/26 323.90 CHF 0.00% 148,409
17/06/26 323.90 CHF 0.00% 289,037
16/06/26 323.90 CHF 0.00% 184,548
15/06/26 323.90 CHF 0.00% 236,877
12/06/26 323.90 CHF 0.00% 194,314
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
319.00CHF
Average target price
358.83CHF
Spread / Average Target
+12.49%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!